GLP-1 Weight Loss Medication Costs in 2026: The Complete Breakdown

Cost is the single biggest barrier to GLP-1 medication access. Brand-name Wegovy lists at over $1,300/month without insurance, pricing millions of eligible patients out of treatment. But the landscape has shifted dramatically in 2026, with compounded alternatives, manufacturer programs, and telehealth models changing the equation.

Brand-name pricing (without insurance)

These prices make brand-name GLP-1s among the most expensive chronic medications in the U.S. Even with manufacturer coupons (Eli Lilly's savings card reduces Zepbound to ~$550/month for eligible patients), out-of-pocket costs remain substantial.

Compounded GLP-1 medications

Compounded semaglutide has emerged as the primary affordability pathway. Under FDA regulations, licensed compounding pharmacies can produce semaglutide formulations during periods of brand shortage or when clinically differentiated:

• Monthly cost: $99 - $299/month depending on dose and provider
• Quality: Produced by 503B outsourcing facilities under FDA oversight with identity, potency, and sterility testing
• Differences: Compounded versions may use semaglutide sodium salt rather than the base form used in Wegovy; clinical equivalence data is limited but pharmacologically similar

Our program offers compounded semaglutide starting at $104.99/month, including physician oversight, medication, and shipping — no hidden fees.

Insurance coverage landscape

Insurance coverage for GLP-1 weight loss medications remains inconsistent:

• Medicare: The Treat and Reduce Obesity Act expanded some coverage in 2025, but access varies by plan
• Commercial insurance: Approximately 40% of employer plans now cover anti-obesity medications, up from 25% in 2023
• State Medicaid: Coverage varies significantly by state — some cover weight management indications, many don't
• Prior authorization: Even when covered, most plans require documentation of BMI, failed lifestyle interventions, and sometimes comorbidities

For detailed insurance guidance, see our GLP-1 insurance coverage guide.

Total cost of treatment vs. cost of obesity

The cost conversation is incomplete without context. The annual medical cost of obesity averages $2,505 per person above normal weight. Over a decade, untreated obesity drives $25,000+ in excess healthcare spending — diabetes management, cardiovascular events, joint replacements, and other weight-related conditions.

Studies have shown that GLP-1 medications reduce healthcare utilization: fewer ER visits, fewer hospitalizations, fewer specialist visits. The medication cost is significant, but it replaces — rather than adds to — the cost of managing obesity's consequences.

How to minimize your costs

1. Check manufacturer programs first. Novo Nordisk and Eli Lilly both offer savings cards and patient assistance programs
2. Ask your employer. Many HR departments are adding anti-obesity medication coverage in response to employee demand
3. Consider telehealth programs.Telehealth providers typically offer lower all-in pricing than traditional clinics by eliminating overhead costs
4. Compare compounded options. If brand-name is unaffordable, licensed compounded semaglutide offers equivalent treatment at 85-90% lower cost

View our transparent pricing — everything included, no surprise bills.

Prices current as of July 2026. Actual costs vary by pharmacy, insurance plan, and region. Linux Health is not affiliated with Novo Nordisk or Eli Lilly.